By Diagnostics World Staff
March 21, 2017 | Kailos Genetics and Illumina have entered a co-marketing agreement with Illumina. Under the terms of the agreement, Illumina will market and promote the Kailos TargetRich line of research solutions for pharmacogenetics targets through its commercial channels.
The agreement includes TargetRich PGxComplete and Kailos Blue. TargetRich PGxComplete is a research use-only reagent that targets a spectrum of relevant genes and provides insights on effectiveness of more than 100 medications based on the resulting genotype. Kailos Blue is the company’s automated data analysis solution – built with one of the industry’s most advanced computing – and reporting software for using TargetRich reagents. As an Illumina BaseSpace Suite ecosystem partner, the solution integrates with and pulls data from BaseSpace Sequence Hub which enables customers to, in real-time, stream their data directly from the sequencing instrument.
TargetRich’s automated approach uses a single tube from start to finish with addition-only protocol, which results in a hands-on time of only 75 minutes. The use of unique molecular identifiers offers extremely high levels of sequence quality analysis, delivering results from research experiments at a low cost per targeted base pair.
“TargetRich chemistry and Kailos Blue analysis tools combined with Illumina’s NGS systems and reagents create seamless workflows,” said Brian Pollock, chief executive officer of Kailos Genetics, in a statement. “The joint solution makes it possible for research laboratories currently standardized on other technologies to convert to NGS. Working with Illumina, we expect to expand the use of NGS solutions to a wider set of laboratories.”
Rob Brainin, vice president and general manager of applied genomics at Illumina added, “We are excited about merging Illumina instruments and reagents with TargetRich reagents to create a solution for our pharmacogenetics research customers. Our collaboration with Kailos is aligned with our mission to provide our customers with innovative solutions at the highest level of quality and to the further adoption of our NGS solutions in the market.”